207 related articles for article (PubMed ID: 26792218)
1. Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status.
Faivre-Finn C; Falk S; Ashcroft L; Bewley M; Lorigan P; Wilson E; Groom N; Snee M; Fournel P; Cardenal F; Bezjak A; Blackhall F
BMJ Open; 2016 Jan; 6(1):e009849. PubMed ID: 26792218
[TBL] [Abstract][Full Text] [Related]
2. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
Faivre-Finn C; Snee M; Ashcroft L; Appel W; Barlesi F; Bhatnagar A; Bezjak A; Cardenal F; Fournel P; Harden S; Le Pechoux C; McMenemin R; Mohammed N; O'Brien M; Pantarotto J; Surmont V; Van Meerbeeck JP; Woll PJ; Lorigan P; Blackhall F;
Lancet Oncol; 2017 Aug; 18(8):1116-1125. PubMed ID: 28642008
[TBL] [Abstract][Full Text] [Related]
3. Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial.
Salem A; Mistry H; Hatton M; Locke I; Monnet I; Blackhall F; Faivre-Finn C
JAMA Oncol; 2019 Mar; 5(3):e185335. PubMed ID: 30520977
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial.
Tay RY; Fernández-Gutiérrez F; Foy V; Burns K; Pierce J; Morris K; Priest L; Tugwood J; Ashcroft L; Lindsay CR; Faivre-Finn C; Dive C; Blackhall F
Ann Oncol; 2019 Jul; 30(7):1114-1120. PubMed ID: 31020334
[TBL] [Abstract][Full Text] [Related]
5. Accelerated, Dose escalated, Sequential Chemoradiotherapy in Non-small-cell lung cancer (ADSCaN): a protocol for a randomised phase II study.
Hatton MQF; Lawless CA; Faivre-Finn C; Landau D; Lester JF; Fenwick J; Simões R; McCartney E; Boyd KA; Haswell T; Shaw A; Paul J
BMJ Open; 2019 Jan; 9(1):e019903. PubMed ID: 30700475
[TBL] [Abstract][Full Text] [Related]
6. [A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy
Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer].
You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):28-34. PubMed ID: 28103970
[TBL] [Abstract][Full Text] [Related]
7. Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study.
Haslett K; Franks K; Hanna GG; Harden S; Hatton M; Harrow S; McDonald F; Ashcroft L; Falk S; Groom N; Harris C; McCloskey P; Whitehurst P; Bayman N; Faivre-Finn C
BMJ Open; 2016 Apr; 6(4):e010457. PubMed ID: 27084277
[TBL] [Abstract][Full Text] [Related]
8. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
9. Moderately Hypofractionated Once-Daily Compared With Twice-Daily Thoracic Radiation Therapy Concurrently With Etoposide and Cisplatin in Limited-Stage Small Cell Lung Cancer: A Multicenter, Phase II, Randomized Trial.
Qiu B; Li Q; Liu J; Huang Y; Pang Q; Zhu Z; Yang X; Wang B; Chen L; Fang J; Lin M; Jiang X; Guo S; Guo J; Wang D; Liu F; Chu C; Huang X; Xie C; Liu H
Int J Radiat Oncol Biol Phys; 2021 Oct; 111(2):424-435. PubMed ID: 33992717
[TBL] [Abstract][Full Text] [Related]
10. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial.
Grønberg BH; Killingberg KT; Fløtten Ø; Brustugun OT; Hornslien K; Madebo T; Langer SW; Schytte T; Nyman J; Risum S; Tsakonas G; Engleson J; Halvorsen TO
Lancet Oncol; 2021 Mar; 22(3):321-331. PubMed ID: 33662285
[TBL] [Abstract][Full Text] [Related]
11. A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.
Salama JK; Hodgson L; Pang H; Urbanic JJ; Blackstock AW; Schild SE; Crawford J; Bogart JA; Vokes EE;
J Thorac Oncol; 2013 Aug; 8(8):1043-9. PubMed ID: 23715301
[TBL] [Abstract][Full Text] [Related]
12. Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial.
Christodoulou M; Blackhall F; Mistry H; Leylek A; Knegjens J; Remouchamps V; Martel-Lafay I; Farré N; Zwitter M; Lerouge D; Pourel N; Janicot H; Scherpereel A; Tissing-Tan C; Peignaux K; Geets X; Konopa K; Faivre-Finn C
J Thorac Oncol; 2019 Jan; 14(1):63-71. PubMed ID: 30391573
[TBL] [Abstract][Full Text] [Related]
13. [Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation
with Concurrent Twice-daily Radiotherapy for Patients
with Limited-stage Small Cell Lung Cancer].
You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):55-60. PubMed ID: 28103974
[TBL] [Abstract][Full Text] [Related]
14. Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial.
Sheikh H; Colaco R; Lorigan P; Blackhall F; Califano R; Ashcroft L; Taylor P; Thatcher N; Faivre-Finn C
Lung Cancer; 2011 Oct; 74(1):75-9. PubMed ID: 21353720
[TBL] [Abstract][Full Text] [Related]
15. Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer.
Bogart JA; Waqar SN; Mix MD
J Clin Oncol; 2022 Feb; 40(6):661-670. PubMed ID: 34985935
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239.
Komaki R; Paulus R; Ettinger DS; Videtic GM; Bradley JD; Glisson BS; Langer CJ; Sause WT; Curran WJ; Choy H
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e531-6. PubMed ID: 22560543
[TBL] [Abstract][Full Text] [Related]
17. Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey.
Levy A; Hendriks LEL; Le Péchoux C; Falk S; Besse B; Novello S; Dingemans AC; Hasan B; Reck M; Berghmans T; Faivre-Finn C;
Lung Cancer; 2019 Oct; 136():145-147. PubMed ID: 31520867
[TBL] [Abstract][Full Text] [Related]
18. Waiting for Big Changes in Limited-Stage Small-Cell Lung Cancer: For Now, More of the Same.
Deek MP; Haigentz M; Jabbour SK
J Clin Oncol; 2023 May; 41(13):2326-2330. PubMed ID: 36821803
[No Abstract] [Full Text] [Related]
19. Treatment Outcomes of Older Participants in a Randomized Trial Comparing Two Schedules of Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC.
Killingberg KT; Grønberg BH; Slaaen M; Kirkevold Ø; Halvorsen TO
J Thorac Oncol; 2023 Jun; 18(6):803-812. PubMed ID: 36716960
[TBL] [Abstract][Full Text] [Related]
20. The influence of time of radio-chemotherapy and other therapeutic factors on treatment results in patients with limited disease small cell lung cancer.
Sas-Korczynska B; Sokolowski A; Korzeniowski S
Lung Cancer; 2013 Jan; 79(1):14-9. PubMed ID: 23153659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
